Minerva Surgical Announces Pricing of Initial Public Offering
Minerva Surgical, a company specializing in women's healthcare, has priced its initial public offering (IPO) at $12.00 per share, totaling $75.0 million for 6,250,000 shares. Trading on the Nasdaq under the symbol UTRS is set to commence on October 22, 2021, with the offering expected to close on October 26, 2021. The underwriters have a 30-day option to purchase an additional 937,500 shares. This IPO aims to fund the continued development of minimally invasive solutions for abnormal uterine bleeding, a significant concern for women's health.
- Initial public offering priced at $12.00 per share, raising $75.0 million.
- Funds are aimed at developing minimally invasive treatment solutions.
- Potential dilution for existing shareholders if underwriters exercise their option for additional shares.
SANTA CLARA, Calif., Oct. 21, 2021 /PRNewswire/ -- Minerva Surgical, Inc. (Minerva Surgical), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of
J.P. Morgan Securities LLC, Piper Sandler & Co., UBS Securities LLC and SVB Leerink LLC are acting as joint book-running managers for the proposed offering.
A registration statement relating to these securities became effective on October 21, 2021. The offering will be made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924; UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, telephone: 1-888-827-7275 or by emailing ol-prospectus-request@ubs.com; SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com. Copies of the final prospectus, when available, related to the offering will be available at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT MINERVA SURGICAL
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of abnormal uterine bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing and size of the proposed initial public offering. Each forward-looking statement is subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described or at all. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Minerva Surgical, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the prospectus included in the registration statement, in the form last filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Minerva Surgical undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minerva-surgical-announces-pricing-of-initial-public-offering-301406407.html
SOURCE Minerva Surgical
FAQ
What is the IPO date for Minerva Surgical's shares (UTRS)?
How much money is Minerva Surgical aiming to raise with its IPO?
What is the public offering price for Minerva Surgical's IPO?
When is the expected closing date for Minerva Surgical's IPO?